Erasca, Inc. (ERAS) Stock Score, Valuation & Financial Research

Erasca, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ERAS

Erasca, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 14.30. These figures are a research snapshot, not a buy or sell recommendation.

What Erasca, Inc. does

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Erasca is a clinical-stage precision oncology company that generates revenue primarily through research and development collaboration agreements. The company focuses on discovering and developing therapies for RAS/MAPK pathway-driven cancers, often entering into licensing or collaboration arrangements that involve upfront payments, milestone payments, and potential future royalties.

Products and services

  • The company is developing a pipeline of precision oncology medicines, including naporafenib (a RAS/MAPK pathway inhibitor), ERAS-0015 (a pan-RAS molecular glue), ERAS-4001 (a pan-KRAS inhibitor), and ERAS-12 (an EGFR antibody).

Customer types

Patients with RAS/MAPK pathway-driven cancers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Tango Therapeutics — Clinical trial collaboration and supply agreement to evaluate vopimetostat in combination with Erasca’s ERAS-0015. Source

Competitors and product-market comparisons

  • Companies developing tyrosine kinase inhibitors — Competitors in the precision oncology space targeting similar oncogenic drivers. Source

Business strengths to evaluate

  • Experienced team of drug discoverers and developers Source
  • Modality-agnostic pipeline targeting RAS/MAPK pathway Source

Business risks and research considerations

  • Dependence on third-party manufacturers for clinical supply Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source · Tango Therapeutics

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ERAS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 14.30
Market capitalization:
4.96B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -287.22M
Free cash flow:
USD -95.58M
Cash:
USD 42.54M
Total debt:
USD 44.71M
EPS:
USD -0.95

What stands out

  • Free cash flow is USD -95.58M, negative for the stored period.
  • The balance sheet shows USD 42.54M of cash versus USD 44.71M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 2.17M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ERAS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ERAS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does ERAS's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for ERAS to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of ERAS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ERAS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.